S W Hung1, G M Adeli, T Arenovich, S H Fox, A E Lang. 1. Movement Disorders Centre, Toronto Western Hospital and Division of Neurology, University of Toronto, Toronto, Canada.
Abstract
OBJECTIVE: To evaluate the perception of patients with Parkinson's disease (PD) regarding dyskinesia. DESIGN: Multicentre survey. SETTING: Tertiary referral centres. PATIENTS: Patients with PD participated in a survey: those not on dopaminergic medications (group I), those on dopaminergic medications without dyskinesia (group II) and those on dopaminergic medications with dyskinesia (group III). INTERVENTION: After a short standardised description and explanation of dyskinesia was provided, patients were asked about the nature and source of prior knowledge of dyskinesia. They were then asked about their perceptions of dyskinesia. Patients in group III were also asked about the duration, the severity of dyskinesia and whether their perception of this problem had changed since its appearance. MAIN OUTCOME MEASURES: Level of concern regarding dyskinesia and whether their perception of dyskinesia would have changed their preference of treatment. Results 259 PD patients completed the survey (group I, 52; group II, 102; group III, 105). Patients with dyskinesia were significantly less concerned about dyskinesia than patients without dyskinesia and were more likely to choose dyskinesia over being parkinsonian. Patients who required fewer changes in medications because of dyskinesia were more likely to choose dyskinesia over parkinsonism. CONCLUSION: Patients with PD experiencing dyskinesia are less likely to be concerned about dyskinesia and more likely to prefer dyskinesia over parkinsonian symptoms than patients without dyskinesia.
OBJECTIVE: To evaluate the perception of patients with Parkinson's disease (PD) regarding dyskinesia. DESIGN: Multicentre survey. SETTING: Tertiary referral centres. PATIENTS: Patients with PD participated in a survey: those not on dopaminergic medications (group I), those on dopaminergic medications without dyskinesia (group II) and those on dopaminergic medications with dyskinesia (group III). INTERVENTION: After a short standardised description and explanation of dyskinesia was provided, patients were asked about the nature and source of prior knowledge of dyskinesia. They were then asked about their perceptions of dyskinesia. Patients in group III were also asked about the duration, the severity of dyskinesia and whether their perception of this problem had changed since its appearance. MAIN OUTCOME MEASURES: Level of concern regarding dyskinesia and whether their perception of dyskinesia would have changed their preference of treatment. Results 259 PDpatients completed the survey (group I, 52; group II, 102; group III, 105). Patients with dyskinesia were significantly less concerned about dyskinesia than patients without dyskinesia and were more likely to choose dyskinesia over being parkinsonian. Patients who required fewer changes in medications because of dyskinesia were more likely to choose dyskinesia over parkinsonism. CONCLUSION:Patients with PD experiencing dyskinesia are less likely to be concerned about dyskinesia and more likely to prefer dyskinesia over parkinsonian symptoms than patients without dyskinesia.
Authors: Jori E Fleisher; Nabila A Dahodwala; Sharon X Xie; Mark Mayo; Daniel Weintraub; Joshua Chodosh; Judy A Shea Journal: J Parkinsons Dis Date: 2016-04-02 Impact factor: 5.568
Authors: Emmanuelle Schmitt; Paul Krack; Anna Castrioto; Helene Klinger; Amelie Bichon; Eugénie Lhommée; Pierre Pelissier; Valerie Fraix; Stephane Thobois; Elena Moro; Pablo Martinez-Martin Journal: Mov Disord Clin Pract Date: 2018-03-23
Authors: Alberto J Espay; Paolo Bonato; Fatta B Nahab; Walter Maetzler; John M Dean; Jochen Klucken; Bjoern M Eskofier; Aristide Merola; Fay Horak; Anthony E Lang; Ralf Reilmann; Joe Giuffrida; Alice Nieuwboer; Malcolm Horne; Max A Little; Irene Litvan; Tanya Simuni; E Ray Dorsey; Michelle A Burack; Ken Kubota; Anita Kamondi; Catarina Godinho; Jean-Francois Daneault; Georgia Mitsi; Lothar Krinke; Jeffery M Hausdorff; Bastiaan R Bloem; Spyros Papapetropoulos Journal: Mov Disord Date: 2016-04-29 Impact factor: 10.338
Authors: Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval Journal: BMC Med Date: 2013-03-20 Impact factor: 8.775